By Application
Hot products 
-
Mouse Anti-APP Recombinant Antibody (5C2A1) (CBMAB-A3314-YC)
-
Mouse Anti-BRD3 Recombinant Antibody (CBYY-0801) (CBMAB-0804-YY)
-
Mouse Anti-FAS2 Monoclonal Antibody (1D4) (CBMAB-0071-CN)
-
Mouse Anti-AMIGO2 Recombinant Antibody (CBYY-C0756) (CBMAB-C2192-YY)
-
Mouse Anti-ATP1B1 Recombinant Antibody (E4) (CBMAB-0463-LY)
-
Mouse Anti-AGK Recombinant Antibody (V2-258056) (CBMAB-M0989-FY)
-
Mouse Anti-AAV8 Recombinant Antibody (V2-634028) (CBMAB-AP022LY)
-
Rat Anti-AChR Recombinant Antibody (V2-12500) (CBMAB-0990-CN)
-
Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY)
-
Mouse Anti-ADGRE2 Recombinant Antibody (V2-261270) (CBMAB-C0813-LY)
-
Mouse Anti-CD63 Recombinant Antibody (CBXC-1200) (CBMAB-C1467-CQ)
-
Mouse Anti-CRTAM Recombinant Antibody (CBFYC-2235) (CBMAB-C2305-FY)
-
Mouse Anti-GDF5 Recombinant Antibody (1F4) (CBMAB-G2740-LY)
-
Mouse Anti-EMP3 Recombinant Antibody (CBFYE-0100) (CBMAB-E0207-FY)
-
Mouse Anti-AKT1/AKT2/AKT3 (Phosphorylated T308, T309, T305) Recombinant Antibody (V2-443454) (PTM-CBMAB-0030YC)
-
Mouse Anti-FN1 Monoclonal Antibody (71) (CBMAB-1241CQ)
-
Mouse Anti-CHRNA9 Recombinant Antibody (8E4) (CBMAB-C9161-LY)
-
Mouse Anti-CSPG4 Recombinant Antibody (CBFYM-1050) (CBMAB-M1203-FY)
-
Mouse Anti-CD8 Recombinant Antibody (C1083) (CBMAB-C1083-LY)
-
Mouse Anti-AKT1 Recombinant Antibody (V2-180546) (CBMAB-A2070-YC)
Carcinoid
Fig.1 Carcinoid
Carcinoid (also carcinoid tumor) is a slow-growing type of neuroendocrine tumor developing from the cells of the neuroendocrine system. The tumors of the midgut (jejunum, ileum, cecum and appendix) are related to carcinoid syndrome. Carcinoid tumors overwhelmingly show as malignant tumor of the appendix, but they are most commonly related to the small intestine, and they can also be found in the stomach and rectum. They are considered to grow in the liver, but this finding is normally a display of metastatic disease from a primary carcinoid occurring somewhere in the body. They have a very mind growth rate compared to most malignant tumors. The median age at diagnosis for all patients with neuroendocrine tumors is 63 years. As the metastatic potential of a coincidental carcinoid is probably low, the current recommendation is for follow up in 3 months with MRI or CT, labs for tumor markers such as serotonin can be applied.
Loading...
Compare
